Kyprolis

Multiple Myeloma, Therapeutic procedure

Treatment

1 FDA approval

17 Active Studies for Kyprolis

Treatment for

Multiple Myeloma

What is Kyprolis

CarfilzomibThe Generic name of this drug

Treatment SummaryCarfilzomib is a medication given by injection that is used to treat adults with relapsed or refractory multiple myeloma. It works by blocking the action of proteasomes, which are proteins responsible for breaking down other proteins. This drug was approved by the FDA in 2012 and can be used alone or in combination with other treatments.

Kyprolisis the brand name

image of different drug pills on a surface

Kyprolis Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Kyprolis

Carfilzomib

2012

Approved as Treatment by the FDA

Carfilzomib, also known as Kyprolis, is approved by the FDA for 1 uses like Multiple Myeloma .

Multiple Myeloma

Used to treat Relapsed Or Refractory Multiple Myeloma in combination with Dexamethasone

Effectiveness

How Kyprolis Affects PatientsCarfilzomib is an intravenous drug that stops the proteasome enzyme from working. After the first dose, proteasome inhibition ranged from 79-89% at 15 mg/m2 to 82-83% at 20 mg/m2 in the blood. In addition, carfilzomib blocked the LMP2 and MECL1 subunits of the immunoproteasome by 26-32% and 41-49%, respectively, at 20 mg/m2. The effects of carfilzomib lasted for at least 48 hours after the first dose. Some people have developed resistance to car

How Kyprolis works in the bodyCarfilzomib is a drug that stops cancer cells from reproducing. It works by blocking the activity of the proteasome, which is a part of the cell responsible for breaking down proteins. When carfilzomib binds to the proteasome, it prevents it from working properly and causes cellular growth to stop. This leads to cell cycle arrest and cell death, reducing the size of tumors. Higher doses can also block other parts of the proteasome, leading to even more effective tumor suppression.

When to interrupt dosage

The proposed dose of Kyprolis is contingent upon the diagnosed ailment, such as Refractory Multiple Myeloma, Waldenstrom Macroglobulinemia and Relapsed Or Refractory Multiple Myeloma. The measure of dosage fluctuates, depending on the delivery procedure (e.g. Injection, powder, lyophilized, for solution or Powder, for solution - Intravenous) featured in the following table.

Condition

Dosage

Administration

Multiple Myeloma

6.0 mg/mL, , 3.0 mg/mL, 60.0 mg, 30.0 mg, 10.0 mg, 10.0 mg/mL

, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution

Therapeutic procedure

6.0 mg/mL, , 3.0 mg/mL, 60.0 mg, 30.0 mg, 10.0 mg, 10.0 mg/mL

Warnings

There are 20 known major drug interactions with Kyprolis.

Common Kyprolis Drug Interactions

Drug Name

Risk Level

Description

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Carfilzomib is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Carfilzomib.

Acteoside

Major

The risk or severity of adverse effects can be increased when Carfilzomib is combined with Acteoside.

Antilymphocyte immunoglobulin (horse)

Major

The risk or severity of adverse effects can be increased when Carfilzomib is combined with Antilymphocyte immunoglobulin (horse).

Axitinib

Major

The serum concentration of Axitinib can be increased when it is combined with Carfilzomib.

Kyprolis Toxicity & Overdose RiskCommon side effects of overdosing on this drug include feeling tired, having low red blood cell count, nausea, low platelet count, difficulty breathing, diarrhea, and fever. The two most serious side effects are low platelet count and fever with a weakened immune system. The highest safe dose of this drug is 15 mg/m^2.

image of a doctor in a lab doing drug, clinical research

Kyprolis Novel Uses: Which Conditions Have a Clinical Trial Featuring Kyprolis?

49 active trials are currently in progress to assess the potential of Kyprolis in alleviating Refractory Multiple Myeloma, Waldenstrom Macroglobulinemia and Therapeutic procedures.

Condition

Clinical Trials

Trial Phases

Multiple Myeloma

16 Actively Recruiting

Phase 1, Phase 2

Therapeutic procedure

0 Actively Recruiting

Patient Q&A Section about kyprolis

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Kyprolis a chemotherapy drug?

"Kyprolis is a second-generation chemotherapy drug used to treat multiple myeloma, which is a type of cancer that affects the plasma cells in the bone marrow."

Answered by AI

What is Kyprolis used for?

"Kyprolis is used to treat multiple myeloma in adults. The drug is given to treat cancer that has come back or didn't get better after past treatments. Kyprolis can be used alone or with other medications. If you've received at least one other cancer treatment in the past, Kyprolis can be used alone."

Answered by AI

What are the side effects of Kyprolis?

"You may experience fatigue, low blood cell and blood platelet levels, shortness of breath, diarrhea, constipation, nausea, fever, or swelling of the extremities."

Answered by AI

Is Kyprolis the same as Velcade?

"Kyprolis was found to be superior to Velcade in patients with relapsed or refractory multiple myeloma, as it more than doubled progression free survival rates."

Answered by AI

Clinical Trials for Kyprolis

Have you considered Kyprolis clinical trials? We made a collection of clinical trials featuring Kyprolis, we think they might fit your search criteria.

Have you considered Kyprolis clinical trials? We made a collection of clinical trials featuring Kyprolis, we think they might fit your search criteria.